Ignite Creation Date:
2024-05-06 @ 6:51 PM
Last Modification Date:
2024-10-26 @ 2:55 PM
Study NCT ID:
NCT05802108
Status:
RECRUITING
Last Update Posted:
2023-04-06
First Post:
2023-03-11
Brief Title:
Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy
Sponsor:
Zibo Central Hospital
Organization:
Zibo Central Hospital
Study Overview
Official Title:
Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In patients with coronary heart disease who were treated with PCSK9 inhibitor evolocumab for intensive lipid-lowering therapy the changes of retinal microvessels were measured with OCTA Optical Coherence Tomography Angiographybefore and after the treatment The specific indicators included retinal microvessel diameter macular areaoptic disc vascular density and FAZFoveal Avascular Zonearea etc to clarify the effect of evolocumab on retinal microvessels after intensive lipid-lowering therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None